Eurobio Scientific presented new cancer treatment data at ESMO 2022

Eurobio Scientific hosted an industry satellite symposium in conjunction with the European Society for Medical Oncology (ESMO) 2022 congress. The event showcased the latest research findings from Myriad Genetics, focusing on treatment decisions for early-stage breast cancer.

The symposium aimed to disseminate new data on genetic signatures and their utility in guiding chemotherapy decisions. The goal is to assist clinicians in making more precise treatment choices and avoiding overtreatment, particularly for premenopausal women diagnosed with ER+/HER2- breast cancer.

Presentations, including one by Dr. Anastasia Constantinidou, highlighted the significance of the EndoPredict test in supporting treatment decisions. Speakers emphasized practical applications and clinical benefits, such as optimizing patient selection for therapies.

The event served as a platform for medical professionals to exchange knowledge and discuss advancements in cancer care. Eurobio Scientific seeks to promote the dissemination of research findings and their application in clinical practice.